Medical Research of Arizona

Scottsdale, Arizona 85251

1 studies enrolling now · 22 studies all time

What they study most

ABPA, Angioedema, Asthma, Chronic Spontaneous Urticaria, HAE, Hereditary Angioedema, Hereditary Angioedema (HAE), Peanut Allergy, Primary Immunodeficiency, Refractory or Unexplained Chronic Cough

Studies at this site

• HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Running, not enrolling
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Enrolling by invitation
• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) — Completed
• Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough — Running, not enrolling
• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema — Completed
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks — Completed
• A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria — Completed
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor — Completed
• A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Running, not enrolling
• Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA — Stopped early
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) — Completed
• Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy — Stopped early
• Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults — NO_LONGER_AVAILABLE
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks — Completed
• A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema — Completed
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America — Completed
• Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) — Completed
• AR101 Real-World Open-Label Extension Study — Completed
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema — Completed
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• TC-6987 for the Treatment of Mild to Moderate Asthma — Completed